Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective

作者：Owen Carolyn^*; Assouline Sarit; Kuruvilla John; Uchida Cassandra; Bellingham Catherine; Sehn Laurie

来源：Clinical Lymphoma Myeloma & Leukemia, 2015, 15(11): 627-634.

DOI：10.1016/j.clml.2015.07.649

• Chronic lymphocytic leukemia
• Duvelisib
• Ibrutinib
• Idelalisib
• Monoclonal antibodies
• Obinutuzumab
• Small molecule inhibitors
• Venetoclax

Chronic lymphocytic leukemia (CLL) is the most common adult lymphoproliferative disorder in Western countries. The current standard of care for CLL is chemoimmunotherapy, typically with fludarabine, cyclophosphamide, and rituximab (FCR). However, most patients with CLL are elderly with comorbidities and are unable to tolerate FCR. In order to choose the best treatment for each individual patient, physicians must balance efficacy with toxicity. In addition, most currently available treatments are ineffective in CLL patients with loss of TP53. Two groups of novel therapeutic agents-anti-CD20 monoclonal antibodies and small molecule inhibitors are attempting to address these issues, and 5 of these agents have progressed to phase 3 trials: obinutuzumab, idelalisib, ibrutinib, venetoclax (ABT-199), and duvelisib (IPI-145). We present the current evidence for these novel agents in the treatment of CLL, along with the perspectives of 4 Canadian oncology experts.

• 出版日期2015-11
• 单位McGill